
Bristol Myers Squibb Unveils Positive Phase 3 Data for Sotyktu in Psoriatic Arthritis
Bristol Myers Squibb Unveils Compelling Late-Breaking Phase 3 Data Highlighting the Efficacy of Sotyktu (Deucravacitinib) in Treating Psoriatic Arthritis Bristol Myers Squibb has announced new late-breaking clinical data from the…












